ArticleCost effectiveness and resource allocation : C/E2019
Willingness to pay for one quality-adjusted life year in Iran.
Article in Cost effectiveness and resource allocation : C/E, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Willingness to Pay per QALY: A Systematic Review of Demand-Side Valuations with a Focus on Age and Disease Severity.Applied health economics and health policy · 2026Pooled it
- Pooled it
- Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression.The European journal of health economics : HEPAC : health economics in prevention and care · 2022Pooled it
- Men's willingness to pay for prostate cancer screening: a systematic review.Systematic reviews · 2020Pooled it
- Value of willingness to pay for a QALY gained in Iran; a modified chained-approach.BMC health services research · 2021Trial
- Cost-effectiveness of plasmapheresis and hemoperfusion in COVID-19 survivors: A six-month follow-up analysis after hospital discharge.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026Article
- Willingness to pay for a quality-adjusted life year in Iran: a systematic review.Cost effectiveness and resource allocation : C/E · 2026Review
- Cost-effectiveness analysis of different types of human papillomavirus vaccination to prevent cervical cancer in Iran.BMC public health · 2025Article
- Challenges in institutionalizing evidence-informed priority setting for health service packages: a qualitative document and interview analysis from Iran.Health research policy and systems · 2024Article
- Willingness to Pay for a Quality-Adjusted Life Year among Gastrointestinal Cancer Patients at a Tertiary Hospital of Vietnam, 2022.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Establishing cost-effectiveness threshold in China: a community survey of willingness to pay for a healthylife year.BMJ global health · 2024Article
- Is vitamin D supplementation program in Iranian schools effective in reducing adolescent depressive symptoms? Cost effectiveness study.BMC public health · 2023Article
- Article
- Economic evaluation of a national vitamin D supplementation program among Iranian adolescents for the prevention of adulthood type 2 diabetes mellitus.BMC complementary medicine and therapies · 2022Article
- Determination of a cost-effectiveness threshold for cancer interventions in Iran.Frontiers in oncology · 2022Article
- An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran.Cost effectiveness and resource allocation : C/E · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent years have witnessed a strong tendency to apply economic evidence as a guide for making health resource allocation decisions, especially those related to reimbursement policies. One such measure is the use of the cost-effectiveness threshold as a benchmark. This study explored the threshold for use in the health system of Iran by determining society's preferences.
methodsA cross-sectional household survey based on the contingent valuation method was administered to a representative general population of 1002 in Tehran, Iran from April to June 2015. The survey was intended to estimate the respondents' willingness-to-pay (WTP) preferences for one quality-adjusted life year (QALY) gained. The valuation scenarios featured 12 vignettes on mild to severe diseases that can change people's quality of life. The mean of WTP for QALY was estimated using different health instruments, and the determinants of such willingness were analyzed using the Heckman selection model.
resultsWTP for QALY varied depending on the severity of a disease and the instrument used to determine health preferences. Mean low health state value were associated with high valuation. The best estimated WTP values ranged from US$1032 to US$2666 and 0.22-0.56 of Iran's local gross domestic product (GDP) per capita in 2014. Except for educational level, significant variables differed across different disease scenarios. Generally, a high health state valuation for target diseases, high income, high educational level, and being married were associated with high WTP for QALY.
conclusionFrom the general public's perspective, the monetary value of QALY for mild to severe diseases with no risk of death was less than one GDP per capita. Therefore, the obtained valuation range is recommended as reference only for the adoption of interventions designed to improve quality of life. Future studies should estimate the threshold of interventions for life-threatening diseases or formulate transparent policies in such contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.